Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus

Jing Xie,1 Ning Li,1 Xiaoyan Jiang,1 Liyin Chai,1 Jian-Jun Chen,2 Wuquan Deng11Department of Endocrinology and Nephrology, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing 400014, People’s Republic of China; 2Institute of Life Sciences, Chongqing Medical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xie J, Li N, Jiang X, Chai L, Chen JJ, Deng W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	repaglinide glimepiride metformin diabetes meta-analysis Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/b013de3547b04ea7b3ef2088d0bb94ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b013de3547b04ea7b3ef2088d0bb94ea
record_format	dspace
spelling	oai:doaj.org-article:b013de3547b04ea7b3ef2088d0bb94ea2021-12-02T03:22:01ZShort-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus1178-7007https://doaj.org/article/b013de3547b04ea7b3ef2088d0bb94ea2019-04-01T00:00:00Zhttps://www.dovepress.com/short-term-efficacy-and-safety-of-repaglinide-versus-glimepiride-as-au-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Jing Xie,1 Ning Li,1 Xiaoyan Jiang,1 Liyin Chai,1 Jian-Jun Chen,2 Wuquan Deng11Department of Endocrinology and Nephrology, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing 400014, People’s Republic of China; 2Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, People’s Republic of ChinaBackground: Consistent evidence is still lacking on which one, glimepiride plus metformin or repaglinide plus metformin, is better in treating type 2 diabetes mellitus (T2DM). Therefore, this study was conducted to compare the short-term efficacy and safety of these two methods in treating T2DM.Methods: The literature research dating up to August 2018 was conducted in the electronic databases. The randomized controlled trials (RCTs) comparing the short-term (treatment period ≤12 weeks) efficacy and safety of these two methods in treating patients with T2DM were included. No language limitation was used in this study. The decreased hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and 2h plasma glucose (2hPG) levels were used as the primary outcome to assess the efficacy, and the adverse events and hypoglycemia were used as the secondary outcome to assess the safety.Results: In total, 11 RCTs composed of 844 T2DM patients were included. The results showed that there were no significant differences in decreasing HbA1c and FPG levels between the two methods, but the estimated standardized mean differences favored the repaglinide plus metformin. Meanwhile, the repaglinide plus metformin was significantly more effective in decreasing 2hPG levels than glimepiride plus metformin. In addition, fewer patients reported adverse events and experienced hypoglycemia in the repaglinide plus metformin group.Conclusion: These results indicated that the repaglinide plus metformin might have some advantages over glimepiride plus metformin in the short-term treatment of patients with T2DM, and should be further explored.Keywords: repaglinide, glimepiride, metformin, diabetesXie JLi NJiang XChai LChen JJDeng WDove Medical Pressarticlerepaglinideglimepiridemetformindiabetesmeta-analysisSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 519-526 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	repaglinide glimepiride metformin diabetes meta-analysis Specialties of internal medicine RC581-951
spellingShingle	repaglinide glimepiride metformin diabetes meta-analysis Specialties of internal medicine RC581-951 Xie J Li N Jiang X Chai L Chen JJ Deng W Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
description	Jing Xie,1 Ning Li,1 Xiaoyan Jiang,1 Liyin Chai,1 Jian-Jun Chen,2 Wuquan Deng11Department of Endocrinology and Nephrology, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing 400014, People’s Republic of China; 2Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, People’s Republic of ChinaBackground: Consistent evidence is still lacking on which one, glimepiride plus metformin or repaglinide plus metformin, is better in treating type 2 diabetes mellitus (T2DM). Therefore, this study was conducted to compare the short-term efficacy and safety of these two methods in treating T2DM.Methods: The literature research dating up to August 2018 was conducted in the electronic databases. The randomized controlled trials (RCTs) comparing the short-term (treatment period ≤12 weeks) efficacy and safety of these two methods in treating patients with T2DM were included. No language limitation was used in this study. The decreased hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and 2h plasma glucose (2hPG) levels were used as the primary outcome to assess the efficacy, and the adverse events and hypoglycemia were used as the secondary outcome to assess the safety.Results: In total, 11 RCTs composed of 844 T2DM patients were included. The results showed that there were no significant differences in decreasing HbA1c and FPG levels between the two methods, but the estimated standardized mean differences favored the repaglinide plus metformin. Meanwhile, the repaglinide plus metformin was significantly more effective in decreasing 2hPG levels than glimepiride plus metformin. In addition, fewer patients reported adverse events and experienced hypoglycemia in the repaglinide plus metformin group.Conclusion: These results indicated that the repaglinide plus metformin might have some advantages over glimepiride plus metformin in the short-term treatment of patients with T2DM, and should be further explored.Keywords: repaglinide, glimepiride, metformin, diabetes
format	article
author	Xie J Li N Jiang X Chai L Chen JJ Deng W
author_facet	Xie J Li N Jiang X Chai L Chen JJ Deng W
author_sort	Xie J
title	Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
title_short	Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
title_full	Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
title_fullStr	Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
title_full_unstemmed	Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
title_sort	short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/b013de3547b04ea7b3ef2088d0bb94ea
work_keys_str_mv	AT xiej shorttermefficacyandsafetyofrepaglinideversusglimepirideasaugmentationofmetforminintreatingpatientswithtype2diabetesmellitus AT lin shorttermefficacyandsafetyofrepaglinideversusglimepirideasaugmentationofmetforminintreatingpatientswithtype2diabetesmellitus AT jiangx shorttermefficacyandsafetyofrepaglinideversusglimepirideasaugmentationofmetforminintreatingpatientswithtype2diabetesmellitus AT chail shorttermefficacyandsafetyofrepaglinideversusglimepirideasaugmentationofmetforminintreatingpatientswithtype2diabetesmellitus AT chenjj shorttermefficacyandsafetyofrepaglinideversusglimepirideasaugmentationofmetforminintreatingpatientswithtype2diabetesmellitus AT dengw shorttermefficacyandsafetyofrepaglinideversusglimepirideasaugmentationofmetforminintreatingpatientswithtype2diabetesmellitus
_version_	1718401814626304000

Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus

Ejemplares similares